david king: rare disease day 2016 conference
TRANSCRIPT
Rare Alliance Canada International Impact
David King, PhD Shire March 9,2016
2
Players Involved
Health Economists
Academic Researchers
Industry
Regulatory Agencies
Payers
Rare Disease Patients
Policy Makers Clinical
Experts
Successful Rare Disease Treatment
3
Why do we need to talk?
Perspective
What is a meaningful endpoint?
Value
Coordination
Disease Understanding
Research Breakthroughs
Ensuring Access
Diagnosis
4
IRDiC
International Rare Disease Research
Consortium
Working to bring 200 new rare
disease treatments by 2020
International with a long history of
Canadian involvement
Adapt-Smart
Private-public consortium
Address drivers, opportunities and
obstacles to adaptive pathways for earlier access
Green Park Collaborative
Multi-stakeholder forum looking at
ways to incorporate real world data into
development
EUPATI
IMI initiative involving 33 institutions
Educate patients on drug development
and registration
Existing Collaborations
5
• Brings all players to the table • Work towards a common
understanding • Build a sustainable solution • Regulatory framework that
provides a common reference point
Benefits For Canada
6
• A single integrated
message • Highlights the scientific
expertise found in Canada
• Brings Canadian biotech to the forefront
• Provides a potential roadmap for other countries
International
7
The End Game